This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Central core disease (congenital myopathy)Central Core Disease (CCD)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.2 | Special Copayment Reduction: V012 | Coverage period: 5 years
B. SynonymsCentral core disease, congenital myopathy (partial), Central Core Myopathy, Core Disease
C. Adult onsetPossibility of first onset in adulthood: low — onset in the neonatal period to childhood, relatively stable course in adulthood; however, cases of delayed diagnosis in adulthood have been reported in carriers of biallelic RYR1 mutations
1. History→ Go to section | First described by Shy & Magee in 1956
2. Causes→ Go to section | RYR1 gene mutations, impaired calcium homeostasis
3. Genetics→ Go to section | Autosomal dominant (mainly); autosomal recessive cases exist
4. Epidemiology→ Go to section | Prevalence about 1/500,000
5. Pathophysiology→ Go to section | RyR1 dysfunction → impaired calcium release from the sarcoplasmic reticulum
6. Symptoms→ Go to section | Hypotonia, proximal muscle weakness, delayed motor development
7. Signs→ Go to section | Scoliosis, hip dislocation, congenital foot deformities
8. Screening→ Go to section | CK normal to mildly elevated, electromyography, muscle MRI
9. Diagnosis→ Go to section | Muscle biopsy (core pathology), gene panel
10. Treatment→ Go to section | Supportive care; prevention of malignant hyperthermia (inhalational anesthetics and succinylcholine contraindicated)
11. Prognosis→ Go to section | Mostly static or slowly progressive course; shortened life expectancy is rare
12. Prevention→ Go to section | Genetic counseling, prenatal testing, MH alert before anesthesia
13. References→ Go to section | 10 key references

1. Historical background

Central core disease (CCD) was first described in 1956 by Shy and Magee in a family spanning five generations with hypotonia and proximal muscle weakness. On muscle biopsy, they found characteristic structures lacking enzyme activity in the center of muscle fibers, namely "cores," and named this a new form of congenital myopathy. Subsequently, in the 1960s–70s, congenital myopathies were established as an independent clinicopathological category, and CCD was recognized as its prototypical disease.

With the development of molecular genetics in the 1990s, it was found that CCD and malignant hyperthermia susceptibility (MHS) are linked to the same chromosomal location, 19q13. In 1993, Quane et al. and Zhang et al. each identified RYR1 gene mutations in MHS families, and it was subsequently shown that RYR1 mutations are also the common cause in CCD patients. In the early 2000s, with advances in whole-exome sequencing technology, various phenotypes due to recessive RYR1 mutations — including multicore disease and some myotubular myopathies — were also reported, and the RYR1 mutation spectrum was redefined as extending beyond simple CCD.

The large-scale clinicopathological-genetic correlation analysis by Jungbluth et al. in 2003 and the 2006 study by Wu et al. confirmed that more than 90% of CCD patients carry RYR1 mutations. Recently, analysis of the selective muscle involvement pattern on muscle magnetic resonance imaging (MRI) has been established as a diagnostic tool, and research on gene therapy and pharmacological targeted therapy is under way.

2. Causes

CCD is caused by mutations in the RYR1 gene, which encodes ryanodine receptor type 1 (RyR1), located in the sarcoplasmic reticulum (SR) of skeletal muscle. The RYR1 gene is located on the long arm of chromosome 19 (19q13.2) and is a large gene consisting of 106 exons. RyR1 is a key component of skeletal muscle excitation-contraction coupling (ECC), responsible for releasing calcium ions from the SR into the cytoplasm in response to action potentials.

CCD-related mutations occur in three main regions of the RYR1 protein — the N-terminal domain, the central domain and the C-terminal transmembrane domain (channel-forming region). In particular, mutations in the C-terminal channel domain (exons 95–106) are mainly expressed in an autosomal dominant form and cause calcium overload in muscle cells through a calcium leak (leaky channel) mechanism. Mutations in the N-terminal and central domains often act through a mechanism of reduced calcium release (loss-of-function) and are associated with autosomal recessive CCD. To date, more than 500 pathogenic RYR1 variants have been reported.

Apart from RYR1, very rarely, mutations in CACNA1S (the α1S subunit of the L-type calcium channel) can also cause a CCD-like phenotype, suggesting that CACNA1S and RyR1 are closely linked functionally. In such cases, malignant hyperthermia susceptibility is also present.

3. Genetics

CCD mainly shows an autosomal dominant inheritance pattern, but autosomal recessive forms are increasingly being reported. Autosomal dominant CCD is usually caused by heterozygous missense mutations in the C-terminal channel-forming region of RYR1 (exons 95–106), with high penetrance but highly variable expressivity.

Autosomal recessive CCD is expressed in a compound heterozygous or homozygous form carrying mutations in both alleles of RYR1. Recessive forms tend to be clinically more severe than dominant forms and are often accompanied by ophthalmoplegia or facial weakness. In addition to CCD, recessive RYR1 mutations can also cause various phenotypes such as multiminicore disease, centronuclear myopathy and congenital fiber-type disproportion.

Prenatal genetic diagnosis and preimplantation genetic testing (PGT) are available, and de novo mutations are not uncommon in families with dominant CCD. Because the mode of inheritance is difficult to predict from muscle biopsy findings alone, full RYR1 gene sequencing (including mRNA analysis) and family history investigation should be carried out together. Cases of incomplete penetrance have also been reported, so carrier parents may be clinically asymptomatic.

Inheritance patternFrequencyMutation locationMain clinical features
Autosomal dominant~70%RYR1 C-terminus (exons 95–106)Proximal muscle weakness, high MH susceptibility
Autosomal recessive~30%Entire RYR1 regionMore severe, facial muscle involvement, MH susceptibility also present

4. General epidemiology

CCD is one of the most common forms of congenital myopathy, with an estimated prevalence of about 1/500,000, but the actual frequency is likely higher because mild cases are underdiagnosed. Sex differences are not clear in the dominant form, but in the recessive form males tend to show a more severe phenotype. Some ethnic clustering (founder mutations) has been reported, but the disease is fairly evenly distributed worldwide.

CCD is estimated to account for about 20–25% of congenital myopathies and makes up a certain proportion of patients referred from neonatal intensive care units (NICUs) for hypotonia. Unlike muscular dystrophies, it progresses slowly and often does not shorten life, so some patients are diagnosed in general pediatrics or adult neurology.

Onset is mostly in the neonatal period to infancy, and some patients first present only in childhood with delayed motor development. It is not uncommon for clinical symptoms to be so mild that the diagnosis is not made until adulthood. In Korea, it is registered and managed under the rare disease Special Copayment Reduction (V012).

5. Pathophysiology

The core pathophysiology of CCD is impaired skeletal muscle calcium homeostasis due to RyR1 dysfunction and the resulting formation of nonfunctional cores within muscle fibers. Muscle excitation-contraction coupling proceeds in the following order: motor nerve action potential → transverse tubule (T-tubule) depolarization → activation of the L-type dihydropyridine receptor (DHPR, α1S subunit, encoded by CACNA1S) → activation of RyR1 via mechanical coupling → Ca²⁺ release from the SR → muscle contraction.

Dominant CCD mutations (mainly C-terminal) keep the RyR1 channel abnormally open (gain-of-function), causing continuous calcium leak even at rest. This leads to calcium depletion within the SR, cytoplasmic calcium overload, mitochondrial dysfunction and oxidative stress. In contrast, in the recessive form, reduced RyR1 protein expression or a loss-of-function mechanism is often predominant.

The mechanism of core formation has not yet been fully elucidated, but it is understood to involve a combination of mitochondrial damage and loss of mitochondrial clustering due to continuous calcium leak, inability of myosin and actin to dissociate, and disruption of sarcomere structure. Pathological cores are typically "structured cores" that are negative on oxidative enzyme stains such as NADH-TR and SDH, and electron microscopy shows disruption of sarcomere structure. Unstructured cores, in which sarcomere structure is relatively preserved, are more common in other RYR1-related myopathies.

That malignant hyperthermia (MH) and CCD arise from mutations in the same gene (RYR1) is explained by a mechanism in which abnormal RyR1 activation is triggered by inhalational anesthetics (halothane, isoflurane, sevoflurane, etc.) or depolarizing muscle relaxants (succinylcholine), setting off a fatal chain reaction of massive calcium release → muscle contraction → hyperthermia → acidosis.

6. Symptoms

The clinical symptoms of CCD show a very wide spectrum, but the typical presentation is as follows.

Neonatal period and infancy

Childhood to adulthood

7. Signs

⚠ Anesthesia alert: Patients with CCD are at very high risk of malignant hyperthermia (MH). Inhalational anesthetics (halothane, isoflurane, sevoflurane, desflurane, etc.) and depolarizing muscle relaxants (succinylcholine) are absolutely contraindicated. For general anesthesia, an MH-non-triggering anesthesia protocol (TIVA, propofol-based) must be used and dantrolene must be prepared.

8. Screening

TestFindings and significance
Serum creatine kinase (CK)Normal or mildly elevated (2–5×ULN). A normal CK does not exclude CCD.
Electromyography (EMG)Myopathic findings (short-duration, low-amplitude polyphasic motor unit potentials); fasciculations rare.
Nerve conduction study (NCS)Normal. No abnormalities of sensory or motor conduction.
Muscle MRISelective fatty infiltration pattern of the thigh quadriceps (especially vastus lateralis). A characteristic pattern on T1-weighted images provides direction before biopsy.
Echocardiography/ECGMyocardial involvement is rare, but cardiomyopathy is occasionally present in recessive forms; baseline evaluation recommended.
Pulmonary function test (PFT)Restrictive pulmonary function pattern when respiratory muscle weakness is present; FVC monitoring.

9. Diagnosis

Confirmation of CCD is based on a clinical–pathological–genetic diagnostic triad.

Muscle biopsy

On light microscopy and histochemical staining (NADH-TR, ATPase, COX, SDH), oxidative enzyme-deficient areas (cores) in the center of muscle fibers are observed, concentrated mainly in type 1 fibers. Type 1 fiber predominance is almost always present. Electron microscopy confirms disruption of sarcomere structure within structural cores.

Molecular genetic testing

In vitro Contracture Test (IVCT)

The halothane-caffeine IVCT can be performed to confirm MH susceptibility, but it is used mainly for MH risk assessment rather than for confirming CCD. The European protocol (EMHG criteria) is applied.

10. Treatment

There is currently no curative treatment for CCD; treatment is based on a supportive, multidisciplinary approach.

Anesthesia safety management (top priority)

Rehabilitation and physical therapy

Orthopedic interventions

Respiratory management

Future treatment outlook

Preclinical studies of RyR1 channel stabilizers (dantrolene, azumolene), antioxidant therapy such as N-acetylcysteine, and AAV vector-mediated gene therapy are underway.

11. Prognosis

Most patients with CCD show a static or very slowly progressive course and often maintain independent ambulation. Weakness is usually mild to moderate, and shortened life expectancy is rare unless severe respiratory failure is present. However, the following factors can worsen the prognosis.

Patients with mild dominant CCD can have normal school life, work, and pregnancy. During pregnancy, planned delivery is needed in preparation for worsening pelvic girdle weakness and anesthesia risk at delivery. On long-term follow-up, respiratory muscle function may gradually decline in some patients after 10–20 years, so continued monitoring is needed.

12. Prevention

Because the genetic cause is clear, fundamental prevention is based on family risk assessment and reproductive choices through genetic counseling.

13. References

  1. Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain. 1956;79(4):610–621. DOI:10.1093/brain/79.4.610
  2. Jungbluth H, et al. Central core disease. Orphanet J Rare Dis. 2007;2:25. DOI:10.1186/1750-1172-2-25 PMID: 17504518
  3. Wu S, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain. 2006;129(Pt 6):1470–1480. PMID: 16621918
  4. Jungbluth H, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology. 2005;65(12):1930–1935. PMID: 16380613
  5. Treves S, et al. Malignant hyperthermia and its phenocopies. Curr Opin Pharmacol. 2005;5(3):326–332. PMID: 15907918
  6. Maggi L, et al. Central core disease: clinical, pathological, and genetic features. J Neurol Neurosurg Psychiatry. 2004;75(2):191–197. PMID: 14670767
  7. Quane KA, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993;5(1):51–55. PMID: 8220421
  8. Amburgey K, et al. Prevalence of congenital myopathies in a representative pediatric United States population. Ann Neurol. 2011;70(4):662–665. PMID: 22002937
  9. Snoeck M, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol. 2015;77(2):343–349. PMID: 25428641
  10. Bharucha-Goebel D, Bonnemann CG. Central core disease. In: Adam MP, et al., eds. GeneReviews®. Seattle: University of Washington; 1993–2024. Updated 2023. NCBI Bookshelf